

FINANCIAL EXPERTS

IN ACTION

ValueTrust acts as independent Fairness Opinion provider to Mologen on the global assignment and co-development agreement with Oncologie

On August 16, 2018 **Mologen AG** ("Mologen"), a German biopharmaceutical company, considered as pioneer in the field of immunotherapy, announced the signing of a term sheet outlining the framework for a global assignment of all intellectual property and rights and an expansion of the existing co-development agreement relating to Mologen's lead compound lefitolimod with **Oncologie Inc.** ("Oncologie").

The potential total deal value could amount to over EUR 1 billion plus low double-digit royalties on net sales. Mologen will receive a near-term consideration of EUR 23 million. This transaction would secure the major part of the funding for the pivotal IMPALA study until read-out, projected for 2020.

In connection with the transaction, ValueTrust rendered a fairness opinion to Mologen's executive and supervisory board.

About Mologen and Oncologie

Mologen AG develops immunotherapies for the treatment of infectious diseases and is listed on the Frankfurt Stock Exchange. Oncologie Inc. is a global oncology biotech company dedicated to biomarker-driven development of large and small molecules with operations in Shanghai and Boston.

About ValueTrust

ValueTrust is the only consulting firm that focuses on business valuation and corporate finance advisory. ValueTrust supports management and investors with truly unbiased advice in transactions, restructurings, disputes/litigations and value management. ValueTrust offers its clients solution-oriented financial advisory services combining both customer-focus and independence with highest standards of quality. ValueTrust's advisory approach is based on years of project experience, the skills of its professionals, a trustful cooperation with its clients as well as the support of industry-experienced senior advisors.

Fairness Opinion

Financial Advisor to

MOLOGEN AG
THE POWER OF IMMUNOTHERAPIES

on a global assignment and co-development agreement with

Oncologie
INC.

Rendered a fairness opinion in connection with the transaction

ValueTrust Financial Advisors SE
Theresienstrasse 1
80333 Munich
Germany

Florian Starck
Steuerberater
Member of the Executive Board
+49 89 388 790 200
+49 172 896 8989
florian.starck@value-trust.com

Mehmet Özbay
Director
+49 89 388 790 140
+49 176 103 057 74
mehmet.oezbay@value-trust.com